Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3541)
All Articles published online
|
Nov 1, 2004 (publication date) through Dec 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Francesco A, Esterita A, Giovanni N, Davide T, Silvia G, Anna M, Francesca L, Marco M, Mariarosa T, Antonio C, Constance M, Davide F, Enrico R, Massimo D, Giuseppe M. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004; 10(21): 3099-3102 [PMID: 15457551 DOI: 10.3748/wjg.v10.i21.3099] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i21/3099.htm |
| Number | Citing Articles |
| 1 |
Davide Festi, Francesca Lodato, Giuseppe Mazzella, Antonio Colecchia. Hepatitis C Virus Disease. 2008; : 215 doi: 10.1007/978-0-387-71376-2_11
|
| 2 |
Evangelos Stournaras, Georgios Neokosmidis, Dimitrios Stogiannou, Andreas Protopapas, Konstantinos Tziomalos. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. European Journal of Gastroenterology & Hepatology 2018; 30(11): 1277 doi: 10.1097/MEG.0000000000001254
|
| 3 |
Nina Kimer, Emilie Kristine Dahl, Lise Lotte Gluud, Aleksander Krag. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open 2012; 2(5): e001313 doi: 10.1136/bmjopen-2012-001313
|
| 4 |
Alfons Billiau. Anti-inflammatory properties of Type I interferons. Antiviral Research 2006; 71(2-3): 108 doi: 10.1016/j.antiviral.2006.03.006
|
| 5 |
Yao-Chun Hsu, Chun-Ying Wu, Jaw-Town Lin. Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 2015; 42(2): 329 doi: 10.1053/j.seminoncol.2014.12.023
|
| 6 |
Gianni Testino, Paolo Borro. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World Journal of Hepatology 2013; 5(10): 521-527 doi: 10.4254/wjh.v5.i10.521
|
| 7 |
Fei Xiong, Qi Wang, Guan-hua Wu, Wen-zheng Liu, Bing Wang, Yong-jun Chen. Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow. Biomarker Research 2022; 10(1) doi: 10.1186/s40364-022-00415-y
|
| 8 |
|
| 9 |
Makoto Nakamuta, Shusuke Morizono, Motoyuki Kohjima, Kazuhiro Kotoh, Munechika Enjoji. Baseline characterization of patients aged 70 years and above with hepatocellular carcinoma. World Journal of Gastroenterology 2005; 11(47): 7512-7514 doi: 10.3748/wjg.v11.i47.7512
|
| 10 |
Soji Shimomura, Shuhei Nishiguchi. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatology Research 2012; 42(1): 22 doi: 10.1111/j.1872-034X.2011.00889.x
|
| 11 |
Alfons Billiau. Interferons: The pathways of discovery. Journal of Clinical Virology 2007; 39(4): 241 doi: 10.1016/j.jcv.2007.04.023
|
| 12 |
José R. Blanco, Antonio Rivero-Juárez. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?. Expert Review of Anti-infective Therapy 2016; 14(11): 993 doi: 10.1080/14787210.2016.1243466
|
| 13 |
Ashwani K. Singal, Amanpal Singh, Sathya Jaganmohan, Praveen Guturu, Rajasekhara Mummadi, Yong–Fang Kuo, Gagan K. Sood. Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis. Clinical Gastroenterology and Hepatology 2010; 8(2): 192 doi: 10.1016/j.cgh.2009.10.026
|
| 14 |
Adriaan J. van der Meer, Heiner Wedemeyer, Jordan J. Feld, Bettina E. Hansen, Michael P. Manns, S. Zeuzem, Harry L.A. Janssen. Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. Journal of Hepatology 2014; 60(1): 191 doi: 10.1016/j.jhep.2013.07.043
|
| 15 |
Yasuhiro Miyake, Yoshiaki Iwasaki, Kazuhide Yamamoto. Meta‐analysis: Reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. International Journal of Cancer 2010; 127(4): 989 doi: 10.1002/ijc.25090
|
| 16 |
Romy Zemel, Assaf Issachar, Ran Tur-Kaspa. The Role of Oncogenic Viruses in the Pathogenesis of Hepatocellular Carcinoma. Clinics in Liver Disease 2011; 15(2): 261 doi: 10.1016/j.cld.2011.03.001
|
| 17 |
Yamini Kalidindi, Jeah Jung, Roger Feldman, Thomas Riley. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C. JAMA Network Open 2020; 3(7): e2011055 doi: 10.1001/jamanetworkopen.2020.11055
|
| 18 |
Sonia Fernández-Veledo, Isabel Huber-Ruano, Ivette Aymerich, Sylvie Duflot, F. Javier Casado, Marçal Pastor-Anglada. Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells. Biochemical Journal 2006; 395(2): 337 doi: 10.1042/BJ20051232
|
| 19 |
Yoshiyuki Ueno, Jose D Sollano, Geoffrey C Farrell. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. Journal of Gastroenterology and Hepatology 2009; 24(4): 531 doi: 10.1111/j.1440-1746.2009.05814.x
|
| 20 |
Mi Na Kim, Beom Kyung Kim, Kwang-Hyub Han. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region. Journal of Gastroenterology 2013; 48(6): 681 doi: 10.1007/s00535-013-0770-9
|
| 21 |
Vivek Kohli, Ashish Singhal, Lenzi Elliott, Sajid Jalil. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transplant International 2012; 25(2): 192 doi: 10.1111/j.1432-2277.2011.01396.x
|
| 22 |
F. AZZAROLI, A. COLECCHI, F. LODATO, D. TRERÈ, M. L. BACCHI REGGIANI, D. FESTI, G. M. PRATI, E. ACCOGLI, S. CASANOVA, M. DERENZINI, E. RODA, G. MAZZELLA. A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis. Alimentary Pharmacology & Therapeutics 2006; 24(1): 129 doi: 10.1111/j.1365-2036.2006.02955.x
|
| 23 |
Yukiko Ito, Natsuyo Yamamoto, Ryo Nakata, Yoshihisa Kato, Masashi Iori, Keisuke Sakai, Tamiko Takemura, Ryosuke Tateishi, Haruhiko Yoshida, Takao Kawabe, Masao Omata. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World Journal of Gastroenterology 2005; 11(45): 7218-7221 doi: 10.3748/wjg.v11.i45.7218
|
| 24 |
C.‐H. Hung, C.‐M. Lee, S.‐N. Lu, J.‐H. Wang, T.‐H. Hu, H.‐D. Tung, C.‐H. Chen, W.‐J. Chen, C.‐S. Changchien. Long‐term effect of interferon alpha‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis. Journal of Viral Hepatitis 2006; 13(6): 409 doi: 10.1111/j.1365-2893.2005.00707.x
|
| 25 |
Mitsuhiko Moriyama, Yasuyuki Arakawa. Treatment of interferon-α for chronic hepatitis C. Expert Opinion on Pharmacotherapy 2006; 7(9): 1163 doi: 10.1517/14656566.7.9.1163
|
| 26 |
Hellan Kwon, Anna S Lok. Does Antiviral Therapy Prevent Hepatocellular Carcinoma?. Antiviral Therapy 2011; 16(6): 787 doi: 10.3851/IMP1895
|
| 27 |
Fai-Meng Sou, Cheng-Kun Wu, Kuo-Chin Chang, Sheng-Nan Lu, Jing-Houng Wang, Chao-Hung Hung, Chien-Hung Chen, Kwong-Ming Kee, Yi-Hao Yen, Ming-Tsung Lin, Ming-Chao Tsai, Tsung-Hui Hu. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. Journal of the Formosan Medical Association 2019; 118(1): 504 doi: 10.1016/j.jfma.2018.10.017
|
| 28 |
Li‐Shuai Qu, Hong Chen, Xiao‐Ling Kuai, Zheng‐Fu Xu, Fei Jin, Guo‐Xiong Zhou. Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C‐related cirrhosis: A meta‐analysis of randomized controlled trials. Hepatology Research 2012; 42(8): 782 doi: 10.1111/j.1872-034X.2012.00984.x
|
| 29 |
Ronald L Koretz, Maria Pleguezuelo, Vasiliki Arvaniti, Pilar Barrera Baena, Ruben Ciria, Kurinchi Selvan Gurusamy, Brian R Davidson, Andrew K Burroughs. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2013; 2013(1) doi: 10.1002/14651858.CD003617.pub2
|
| 30 |
Chang Seok Bang, Il Han Song. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterology 2017; 17(1) doi: 10.1186/s12876-017-0606-9
|
| 31 |
Stacey Prenner, Laura Kulik. HCC: Where Does HCV Therapy Play a Role?. Current Hepatology Reports 2016; 15(1): 17 doi: 10.1007/s11901-016-0292-z
|
| 32 |
Roger Chou, Tracy Dana, Rongwei Fu, Bernadette Zakher, Jesse Wagner, Shaun Ramirez, Sara Grusing, Janice H. Jou. Screening for Hepatitis C Virus Infection in Adolescents and Adults. JAMA 2020; 323(10): 976 doi: 10.1001/jama.2019.20788
|
| 33 |
Francesca Lodato, Giuseppe Mazzella, Davide Festi, Francesco Azzaroli, Antonio Colecchia, Enrico Roda. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World Journal of Gastroenterology 2006; 12(45): 7239-7249 doi: 10.3748/wjg.v12.i45.7239
|